The IMID Forum
Discussing PsA: DISCOVER-2 and BE OPTIMAL/BE COMPLETE post-hoc analyses
Nov 28, 2024
Professors discuss groundbreaking studies in Psoriatic Arthritis, focusing on bimekizumab's rapid efficacy for pain and fatigue relief. They delve into long-term results from guselkumab, revealing sustained clinical improvements over two years. The importance of personalized treatment strategies is highlighted, especially concerning the impact of background therapies. They also emphasize patient-reported outcomes, demonstrating how insights into patients' experiences can significantly enhance care and treatment approaches.
30:53
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Bimikizumab demonstrated significant early improvements in pain, fatigue, and physical function in PsA patients, enhancing overall quality of life.
- Guselkumab showed remarkable durability in clinical improvements for joint and skin symptoms, reinforcing its potential as a long-term treatment for PsA.
Deep dives
Durability of Guzelcomab in Active Psoriatic Arthritis
A post-hoc analysis of biologic naive patients in the DISCOVER2 trial examined the persistent effects of Guzelcomab administered every eight weeks for active psoriatic arthritis (PSA). The results indicated that between 93 to 99 percent of patients maintained clinical improvement by the end of the eight-week dosing intervals, demonstrating significant durability in joint disease and pain relief. Additionally, a substantial number of patients achieved marked improvements in skin conditions, with a 68% probability of maintaining this improvement for 100 weeks post-treatment. These findings reinforce Guzelcomab's potential as a reliable long-term treatment option for managing both joint and skin manifestations in PSA.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
